LHLaura Hondebrink

Laura Hondebrink

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Hondebrink has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends in new psychoactive substance poisonings in the Netherlands: A 14‐year retrospective analysis (2012–2025)

    by Johanna J. Nugteren‐Van Lonkhuyzen, Irma S. van Den Hengel‐Koot, Claudine C. Hunault, Dylan W. de Lange, Antoinette J. H. P. van Riel, Laura Hondebrink

    Background and aims: Data on the presence of new psychoactive substances (NPS) mainly originate from drug‐checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands. We investigated temporal trends in NPS poisonings reported to the Dutch Poisons Information Center (DPIC) between 2012 and 2025 and compared these trends across NPS categories. Design: National observational study based on retrospective extraction of recreational drug poisonings (including NPS) from the DPIC database from 2012 to 2025. The DPIC is not accessible to the general public and reporting by healthcare professionals is voluntary. Setting/cases: The DPIC database contains standardized case report forms with anonymous patient data and individually (self‐)reported substance exposures (not ICD‐coded, not analytically confirmed). All cases concerning human exposures to recreational drugs recorded in the DPIC database were included. Measurements: Primary outcomes were the annual number and annual incidence rate of NPS poisonings reported to the DPIC, relative to the annual number of all recreational drug poisonings. Secondary outcomes were incidence rates of specific (categories of) NPS over time. Predictor was the year of report. Findings: Between 2012 and 2025, healthcare professionals reported 19 316 recreational drug poisonings, including 4289 NPS‐related poisonings, while seeking advice on patient management. The annual number of NPS poisonings increased from 32 in 2012 to 829 in 2025. Between 2012 and 2025 the annual incidence rate of NPS poisonings increased statistically significantly by 19% per year [incidence rate ratio = 1.19; 95% confidence interval (CI) = 1.15–1.23]. A higher incidence rate of NPS poisonings was observed in July and December. Cathinones, phenethylamines and benzodiazepines represented 83% of all NPS poisonings. Benzodiazepines were predominant in 2012 and 2024, phenethylamines from 2013 to 2018 and cathinones from 2019 to 2023 and in 2025. The total number of unique NPS notified to the DPIC increased from 17 in 2012 to 176 in 2025. Poisonings with 3‐methylmethcathinone (3‐MMC), bromazolam, 4‐fluoroamphetamine (4‐FA), 4‐bromo‐2,5‐dimethoxyphenethylamine (2C‐B) and 4‐methylmethcathinone (4‐MMC, mephedrone) were reported most frequently (5–22% of 4289 NPS poisonings). Poisonings with arylcyclohexylamines, cannabinoids, opioids, arylalkylamines, tryptamines (indolalkylamines), piperidines and pyrrolidines and other substances were rare (every category <5% of 4289 NPS poisonings). No poisonings with aminoindanes or piperazines were reported from 2012 to 2025. Conclusions: The annual incidence rate of new psychoactive substances poisonings reported to the Dutch Poisons Information Center increased by 19% per year between 2012 and 2025. The predominant categories and specific substances involved changed markedly over time.

  • Open Access

    Deliberate self-poisoning in four European countries: retrospective analysis of poison centre data

    by Arjen Koppen, Katrin Faber, Laura Hondebrink, Mark Lawrence Zammit, Maren Hermanns-Clausen, Dominique Vodovar

    Within six years, poison centres reported 1,783,858 cases, and one in ten (177,921 cases) involved deliberate self-poisonings. Rates varied across countries, ranging from 8% in France to 23% in the Netherlands. Cases with deliberate self-poisoning remained stable between 2017 and 2020, with an increase observed from 2021 to 2022. Females accounted for 70% of cases, rising to 84% among children/adolescents of 5-17 years. Rates among children/adolescents of 5-17 years increased significantly after 2020 in all countries, largely due to a strong increase among females. Substances involved varied by country, but alcohol, benzodiazepines, and antidepressants dominated in adults, while paracetamol and ibuprofen dominated among children/adolescents of 5-17 years. Common trends in deliberate self-poisoning, particularly in different age groups, are highlighted and challenges of cross-national data harmonisation in European poison centres are demonstrated. Deliberate self-poisoning represented a substantial proportion of poisoning cases, with a sharp rise after 2020, especially among children/adolescent females using readily available over-the-counter non-prescription medicines. These findings underscore the need for targeted prevention strategies and demonstrate the value of coordinated data collection. Expanding collaboration across additional countries could enhance monitoring, strengthen trend analyses, and inform public health interventions.

  • Open Access

    Recreational drug poisonings reported to six European poison centres from 2021 to 2024

    by Laura Hondebrink, Katrin Faber, Aza Kader, Pardeep Singh Jagpal, Tara Arif, Maren Hermanns-Clausen

    Recreational drug poisonings pose a growing public health concern. European-level data remain limited, although poison centres are well placed to monitor related health incidents. This study analysed temporal trends in recreational drug poisonings reported to six European poison centres. Aggregated retrospective data were collected over four years (2021-2024) from poison centres in Austria, Freiburg (Germany), the Netherlands, Sweden, Switzerland, and the United Kingdom. Cases involving 11 recreational drugs (amfetamine, cocaine, delta-9-tetrahydrocannabinol, gamma-hydr-oxybutyrate, heroin, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymetamfetamine, metamfetamine, poppers, and psilocybin) were included. Annual rates of recreational drug exposures were calculated relative to all poisoned patients, and trends were analysed using linear regression. From 2021 to 2024, the six centres recorded 1,051,287 poisonings, of which 23,779 (2.3%) involved recreational drugs. The rate of recreational drug exposures increased from 1.8% (n = 4,581) in 2021 to 2.6% (n = 7,229) in 2024, mainly driven by the increases in Austria, Freiburg, and the United Kingdom. Rates ranged from 1.3% (Austria) to 2.8% (Netherlands) in 2021 and from 1.9% (Austria) to 3.6% (Freiburg) in 2024. Delta-9-tetrahydrocannabinol, cocaine, amfetamine, and 3,4-methylenedioxymetamfetamine were most frequently implicated. Increasing rates were observed for delta-9-tetrahydrocannabinol (Freiburg, Austria), cocaine (Freiburg, United Kingdom), amfetamine (Freiburg, Sweden), and ketamine (Austria, Freiburg, United Kingdom). In 2024, amfetamine poisonings peaked in Freiburg (0.63%) and Sweden (0.94%), cocaine in Freiburg (0.78%) and the United Kingdom (0.74%), and ketamine in the Netherlands (0.42%) and the United Kingdom (0.24%). Although recreational drug poisonings comprised a small proportion of poison centre calls (∼3%), a significant increase was observed between 2021 and 2024, underscoring their value in toxicovigilance and early identification of emerging drug trends. Delta-9-tetrahydrocannabinol, cocaine, amfetamine, and 3,4-methylenedioxymetamfetamine were most frequently reported, with notable national differences. Coordinated European monitoring of recreational drug poisonings may support timely public health interventions and prevention strategies.


  • Open Access

    Incidents with recreational nitrous oxide use before and after legislation: poisonings and police incidents in the Netherlands between 2020 and 2025

    by L. Hondebrink, J.J. Nugteren-Van Lonkhuyzen, I.S. van Den Hengel-Koot, A.J.H.P. van Riel, P. Jansen, M.H.J.C. Coenraads


  • Open Access

    Advancing toxicovigilance of recreational drugs, including new psychoactive substances, by using data from four European poison centres

    by Aza Kader, Maren Hermanns-Clausen, Antoinette van Riel, Katrin Faber, Laura Hondebrink

    Common recreational drugs and new psychoactive substances pose challenges to public health. This study investigated the feasibility of merging cases of recreational drug poisoning reported to European poison centres. Four European poison centres (Freiburg, Germany; the Netherlands; Sweden and Switzerland) collaborated in a retrospective, observational study. We collected aggregated data on poisonings with 11 common recreational drugs and case-by-case data on poisonings with new psychoactive substances in 2021 by using anonymized data from electronic case reports. In 2021, 2.0% of the poison centre calls involved poisonings with recreational drugs. The poison centres were contacted about 3,705 patients, involving 4,380 drug exposures, of which 3,708 were common recreational drugs, and 672 were new psychoactive substances. Per million inhabitants, the poisoning rate with common recreational drugs varied between 48 (Freiburg) and 145 (Sweden). Poisonings with amfetamine (22%), cocaine (20%), all delta-9-tetra-hydrocannabinol-containing preparations (20%), and 3,4-methylenedioxymetamfetamine (13%) exposures were most frequent. The poisoning rate per million inhabitants with new psychoactive substances varied between two (Switzerland) and 29 (Netherlands). Cathinones (43%), designer benzodiazepines (28%), and phenethylamines (13%) were the most commonly involved new psychoactive substance classes. Symptoms following cathinone poisoning were tachycardia (35%) and hypertension (13%), while following designer benzodiazepines, somnolence was most prominent (38%). The majority of users of new psychoactive substances were male (67%), 55% were between 18 and 30 years, and 8% involved minors (<18 years). This study showed the feasibility of merging data on recreational drug poisoning collected by poison centres in four countries. Despite underestimating the overall incidence of drug-related health incidents, poison centre data offers national coverage, unlike other data sources, such as drug-related emergency department visits. This multi-centre, multi-national study reported a substantial annual number of recreational drug poisonings, with a variable proportion of new psychoactive substances. It shows that poison centre data offers detailed insights into exposures to common recreational drugs and new psychoactive substances, user characteristics, and symptoms. It can be used for comprehensive monitoring of drug-related health incidents on a multi-national level.


  • Open Access

    Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020

    by Mitchell L. Waters, Paul I. Dargan, Christopher Yates, Alison M. Dines, Florian Eyer, Isabelle Giraudon, Fridtjof Heyerdahl, Knut Erik Hovda, Matthias E. Liechti, Òscar Miró, et al.

    Cannabis is the most common recreational drug worldwide and synthetic cannabinoid receptor agonists are currently the largest group of new psychoactive substances. The aim of this study was to compare the clinical features and outcomes of lone acute cannabis toxicity with lone acute synthetic cannabinoid receptor agonist toxicity in a large series of presentations to European emergency departments between 2013-2020. Self-reported drug exposure, clinical, and outcome data were extracted from the European Drug Emergencies Network Plus which is a surveillance network that records data on drug-related emergency department presentations to 36 centres in 24 European countries. Cannabis exposure was considered the control in all analyses. To compare the lone cannabis and lone synthetic cannabinoid receptor agonist groups, univariate analysis using chi squared testing was used for categorical variables and non-parametric Mann-Whitney U- testing for continuous variables. Statistical significance was defined as a P value of < 0.05. Between 2013-2020 there were 54,314 drug related presentations of which 2,657 were lone cannabis exposures and 503 lone synthetic cannabinoid receptor agonist exposures. Synthetic cannabinoid receptor agonist presentations had statistically significantly higher rates of drowsiness, coma, agitation, seizures and bradycardia at the time of presentation. Cannabis presentations were significantly more likely to have palpitations, chest pain, hypertension, tachycardia, anxiety, vomiting and headache. Emergency department presentations involving lone synthetic cannabinoid receptor agonist exposures were more likely to have neuropsychiatric features and be admitted to a psychiatric ward, and lone cannabis exposures were more likely to have cardiovascular features. Previous studies have shown variability in the acute toxicity of synthetic cannabinoid receptor agonists compared with cannabis but there is little comparative data available on lone exposures. There is limited direct comparison in the current literature between lone synthetic cannabinoid receptor agonist and lone cannabis exposure, with only two previous poison centre series and two clinical series. Whilst this study is limited by self-report being used to identify the drug(s) involved in the presentations, previous studies have demonstrated that self-report is reliable in emergency department presentations with acute drug toxicity. This study directly compares presentations with acute drug toxicity related to the lone use of cannabis or synthetic cannabinoid receptor agonists. It supports previous findings of increased neuropsychiatric toxicity from synthetic cannabinoid receptor agonists compared to cannabis and provides further data on cardiovascular toxicity in lone cannabis use.


  • Open Access

    High Incidence of Signs of Neuropathy and Self-Reported Substance Use Disorder for Nitrous Oxide in Patients Intoxicated with Nitrous Oxide

    by Johanna J. Nugteren – Van Lonkhuyzen, Lot van der Ben, Irma S. van Den Hengel- Koot, Dylan W. de Lange, Antoinette J.H.P. van Riel, Laura Hondebrink

    Introduction: The number of patients with excessive nitrous oxide (N2O) use and neurological disorders has been rising, indicating an addictive potential of N2O. We studied the incidence of self-reported substance use disorder (SUD)-related symptoms, signs of neuropathy, and the patterns of use in N2O-intoxicated patients. Methods: The Dutch Poisons Information Center (DPIC) provides information by telephone on the management of intoxications to healthcare professionals. Retrospective data on signs of neuropathy and patterns of use were collected for all N2O intoxications reported to the DPIC in 2021 and 2022. Frequent and heavy use were self-reported as “often/frequent/weekly use” and as “use of tanks or >50 balloons/session,” respectively. From this cohort, we included patients with excessive N2O use or signs of neuropathy in a prospective observational cohort study. Online surveys were sent 1 week, 1 month, and 3 months after DPIC consultation. The survey included the drug use disorder questionnaire (validated to measure self-reported substance abuse [SA] and substance dependence [SD] based on Diagnostic and Statistical Manual of Mental Disorders [DSM]-IV-TR criteria) and questions on patterns of use and signs of neuropathy. DSM-IV-TR criteria were translated to DSM-V criteria to score for mild, moderate, or severe SUD, with 2–3, 4–5, or ≥6 symptoms, respectively. Results: We included 101 N2O-intoxicated patients in the retrospective study. Of these, 41% showed signs of neuropathy (N = 41), 53% used N2O tanks to fill balloons (N = 53), 71% used them frequently (N = 72), and 76% used them heavily (N = 77). We included 75 patients in the prospective study and 10 (13%) completed the first survey. All 10 patients fulfilled the criteria for SA and SD (DSM-IV-TR, median number of questions answered “yes” = 10/12), all used N2O tanks to fill balloons, and 90% (N = 9) experienced signs of neuropathy. After 1 and 3 months, 6/7 and 1/1 patients, respectively, continued to fulfill SA and SD criteria. Translating to DSM-V criteria, 1/10 patients fulfilled the criteria for (self-reported) mild SUD, 1/10 patients for moderate SUD, and 8/10 patients for severe SUD, 1 week after consultation. Conclusion: The high proportion of N2O-intoxicated patients reporting frequent and heavy use of N2O indicates an addictive potential of N2O. Although follow-up rate was low, all patients fulfilled self-reported SA, SD (DSM-IV-TR), and SUD (DSM-V) criteria for N2O. Somatic healthcare professionals treating patients with N2O intoxications should be aware of possible addictive behavior in patients. The screening, brief intervention, and referral to treatment approach should be considered to treat patients with self-reported SUD symptoms.


  • Open Access

    Effect of the first wave of COVID-19 on Poison Control Centre activities in 21 European countries: an EAPCCT initiative

    by L. Hondebrink, M. Zammit, L. C. G. Høgberg, M. Hermanns-Clausen, D. Lonati, K. Faber, on behalf of the EAPCCT COVID-19 Research Group

    Public health emergencies often affect Poison Control Centre (PCC) operations. We examined possible effects of the coronavirus disease 2019 (COVID-19) pandemic on call volume, call characteristics,...